“OncoOne has had a successful start to 2023, with the lead oxMIF mAb for solid tumors, ON203, being featured in the American Association for Cancer Research’s journal Molecular Cancer Therapeutics. The summary of ON203’s design and preclinical experiments has been published online in conjunction with

We are delighted to announce Friedmund Bachmann’s well-deserved promotion to the role of Vice President CMC at OncoOne, effective April 1, 2023! With a remarkable career spanning renowned companies such as Baxter, Baxalta, Shire, and Takeda, Friedmund has gathered a wealth of experience and held

We are thrilled to announce the well-deserved promotion of Christine Landlinger-Schubert to the role of Vice President Preclinical and Translational R&D at OncoOne, effective April 1, 2023! With nearly 15 years of experience in the biotech industry, Christine has consistently showcased her exceptional skills and

We are thrilled to announce that Maroua Ferhat, PhD has been awarded the promotion to Senior Scientist effective March 1, 2023 Maroua has been with the company for a year and a half and has progressively taken on more responsibility in our biology group, where

We are pleased to announce the promotion of Maria Reitzinger to Head of Finance and Administration, effective March 1, 2023. Maria joined OncoOne in June 2020 as an Executive Assistant and has taken on increasing responsibilities over the past two years. She has a professional background

“In the fourth quarter of 2022, we traveled around the world sharing our message about the potential of oxMIF as an immuno-oncology and inflammation target. With our Series B raise underway and completion of several value-building projects I value this opportunity to update you on